Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer

Sunitinib has been registered for the treatment of advanced renal cell cancer (RCC). As patient inclusion was highly selective in previous studies, experience with sunitinib in general oncological practice remains to be reported. We determined the efficacy and safety of sunitinib in patients with ad...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: van der Veldt, A A M, Boven, E, Helgason, H H, van Wouwe, M, Berkhof, J, de Gast, G, Mallo, H, Tillier, C N, van den Eertwegh, A J M, Haanen, J B A G
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group 2008
Témata:
Clinical Study
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2480961/
https://ncbi.nlm.nih.gov/pubmed/18594533
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6604456
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky